A high throughput protein expression platform has been developed which can be used to produce the complete proteome from F. tularensis, and the resulting proteome will be applied to the general problem of identifying potent vaccine antigens affective against F. tu/arensis infection. The proteome expression platform uses our GeneActivation by PCR (GAP) approach and a novel high throughput in vivo recombination cloning method for generating transcriptionally active genes that can be used directly in in vitro transfection assays, and in vivo. The system allows for the addition of poly-Histidine tags and other tags into the protein products so that they can be conveniently purified and detected, and the system has been adapted to a robotics workstation enabling 384 different purified proteins to be produced and purified in 1 day. The F. tularensis proteome will be prepared in 2 forms. The first form will be on protein """"""""chips"""""""" and the chips will be used to quantify serum antibody titers from infected or vaccinated, humans and animals, against each of the -2000 individual F. tularensis antigens. For the second proteome format, each individual protein will be purified and stored in 96-well microtiter plates in a form that will enable them to be delivered to, and processed by antigen presenting cells. These antigen presenting cells will then be used as targets in an ELISPOT assay to determine the level of antigen specific T-cells against each individual antigen from infected or vaccinated, humans and animals. This quantitative humoral and cellular immune response scan will produce a complete profile of the immune response against F. tularensis in humans and experimental animals. Mice will be immunized with the Live Vaccine Strain (LVS) of F. tularensis, and the humoral and cellular immune responses of the surviving animals will be scanned. The animals will be challenged with a highly virulent strain of F. tularensis (strain SchuS4) and the immune responses of the surviving animals will be re-scanned. Comparing the immune responses from animals that survive lethal challenge with those that don't survive will identify key antigens that are important for conferring protection. These data will be used together with other immunological and bioinformatics criteria to identify likely candidate antigens for a DNA vaccine or a protein subunit vaccine. The assays developed in mice will be adapted to human tissue samples, and the humoral and cellular vaccine antigen potency indexes will be determined in a group of humans previously immunized with the LVS vaccine. Since the immune response induced by the LVS vaccine is known to have protective activity against F. tularensis infection, the responsive antigens identified by the Vaccine Antigen Scan will be candidates for use in a DNA or subunit vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI056464-04
Application #
7068501
Study Section
Special Emphasis Panel (ZAI1-ALR-M (M3))
Program Officer
Mukhopadhyay, Suman
Project Start
2003-08-01
Project End
2008-01-31
Budget Start
2006-02-01
Budget End
2008-01-31
Support Year
4
Fiscal Year
2006
Total Cost
$867,601
Indirect Cost
Name
University of California Irvine
Department
Miscellaneous
Type
Organized Research Units
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Jing, Lichen; Schiffer, Joshua T; Chong, Tiana M et al. (2013) CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence. J Virol 87:2617-27
Vigil, Adam; Davies, D Huw; Felgner, Philip L (2010) Defining the humoral immune response to infectious agents using high-density protein microarrays. Future Microbiol 5:241-51
Magnan, Christophe N; Zeller, Michael; Kayala, Matthew A et al. (2010) High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics 26:2936-43
Davies, D Huw; Wyatt, Linda S; Newman, Frances K et al. (2008) Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 82:652-63
Jing, Lichen; Davies, D Huw; Chong, Tiana M et al. (2008) An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol 82:7120-34
Chen, Guanghui; Felgner, Philip L; Guan, Zhibin (2008) Efficient catalytic synthesis of dendritic polymers having internal fluorescence labels for bioconjugation. Biomacromolecules 9:1745-54
Doolan, Denise L; Mu, Yunxiang; Unal, Berkay et al. (2008) Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8:4680-94
Sundaresh, Suman; Randall, Arlo; Unal, Berkay et al. (2007) From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics 23:i508-18
Lu, Zhaohua; Roche, Marly I; Hui, Julia H et al. (2007) Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett 112:92-103
Davies, D Huw; Molina, Douglas M; Wrammert, Jens et al. (2007) Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7:1678-86

Showing the most recent 10 out of 14 publications